NSE filing, NSE: ATMASTCO. Summary written from the filing by ALFA Finder's alert engine.
Atmastco Ltd: key numbers
- Share price
- ₹102.75
- Market cap
- ₹268.8 Cr
- Revenue (annual)
- ₹292.6 Cr
- Net profit (annual)
- ₹19.05 Cr
- P/E (TTM)
- 14.1×Sector 31.3×
- Promoter holding
- 62.54%-3.60% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Atmastco Ltd
All →Atmastco Other Announcement
Atmastco Limited has received approval from the Registrar of Companies for a 2-month and 15-day extension to hold its Annual General Meeting.
Atmastco Bags New Order from Ministry of Defence & Ministry of Power
Atmastco Limited's subsidiary secured its first order from the Ministry of Defence and Ministry of Power. The contract involves supplying bullet-resistant helmets, marking entry into the defence sector.
- From
- Ministry of Defence & Ministry of Power
Atmastco Management Change
Atmastco Limited appointed Mr. Ankit Mishra as Company Secretary and Compliance Officer, effective September 12, 2026. This appointment follows the board meeting held on the same day.
Atmastco Bags ₹66 Cr Order from Reliance Industries Limited
Atmastco Ltd secured an order from Reliance Industries Limited for supplying pre-fabricated structural steel, valued at approximately ₹66.00 Crore, with execution by March 2027.
- Value
- ₹66.00 Cr
- From
- Reliance Industries Limited
- Execution
- Up to March 2027
Atmastco Management Change
Atmastco Limited appointed Sarvesh Kumar as the new Chief Financial Officer, succeeding Venkataraman Ganesan, who resigned as CFO while continuing as Executive Director.
Atmastco Q1 FY27 Results: Net Profit ₹1.4 Cr, Up 55.6% YoY
Atmastco Ltd reported revenue from operations of ₹42.7 Cr (-18.7% YoY) and net profit of ₹1.4 Cr (+55.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.4 Cr · +55.6% YoY
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.